Purified exosomal product triggers wound healing in preclinical model

Written by Heather Jones

Ischemic wounds in preclinical models have been healed using an acellular product developed by the Mayo Clinic (MN, USA), with normal scar-free skin after treatment. Published in the journal Theranostics, the team documented restoration of skin integrity, hair follicles, sweat glands, skin oils and normal hydration, laying the foundation for clinical studies to test the safety of using the purified exosomal product (PEP) for would healing in patients. Chronic ischemic wounds are common among individuals with conditions such as diabetes, pressure ulcers, hardening of arteries, traumatic injury or side effects of radiation therapy. While the current standard treatments of wound...

To view this content, please register now for access

It's completely free